Hope leads to lower depression and anxiety and is associated with improved quality of life of cancer patients. In this
study, Hope Scale (HS) was translated into Malay, and the psychometric properties of the Malay version of the Hope
Scale were investigated among Malaysian cancer patients. Concurrent translation and back translation of the original
English version of the Hope Scale were performed, and the Malay version was administered to 195 cancer patients
with different cancer diagnoses at baseline assessment and 2 months later at follow-up. The Hope Scale (Malay) total
score (Cronbach’s α = 0.72; intraclass correlation coefficient (ICC) = 0.67) and its domains (Cronbach’s α [pathway] =
0.7; Cronbach’s α [agency] = 0.7; ICC[Pathway] = 0.64; ICC[Agency] = 0.70) demonstrated acceptable internal consistencies and
test-retest reliability. Convergent and discriminant validities were also achieved by the Hope Scale (Malay). The Hope
Scale (Malay) demonstrated construct validity, as confirmatory factor analysis demonstrated that the items in the Hope
Scale (Malay) best fit into two domains, which was true for the original English version. The Hope Scale (Malay) had
acceptable psychometric properties and thus is suitable for assessing hope in Malaysian cancer patients.
Objective: It is important to investigate the association between spousal support
and psychology of cancer patients, thus a validated instrument to measure the
degree of perceived spousal support is required. We translated and evaluated the
psychometric properties of the Sources of Social Support Scale-Malay version
(SSSS-Malay) among Malaysian cancer patients.
Methods: In this study, the
SSSS-Malay and Hope Scale-Malay [used to compare with the SSSS-Malay to
assess discriminant validity] were administered to 195 Malaysian cancer patients
during baseline assessment. The SSSS-Malay was re-administered 2 months
after the baseline assessment during follow-up.
Results: The SSSS-Malay total
score (Cronbach’s α = 0.70, intraclass correlation coefficient (ICC) = 0.72) and
its domains (Cronbach’s α ranging from 0.70 to 0.83, intraclass correlation
coefficient ranging from 0.6 to 0.76) exhibited good internal consistencies and
good test-retest reliability. The SSSS-Malay also demonstrated good convergent
and discriminant validities. However, confirmatory factor analysis of the SSSSMalay
showed that it was best fit into a 3-factor model instead of the 4-factor
model of the original English version.
Conclusion: The SSSS-Malay
demonstrated good psychometric properties for use in Malaysian cancer
patients.
Introduction: Posttraumatic growth (PTG) is a positive psychological change in
life that occurs as a result of struggle with highly challenging life crises. There is
a growing need to explore posttraumatic growth (PTG) in cancer patients, as
higher PTG may enhance well-being of patients.
Objectives: The aim of this
study was to translate the Posttraumatic Growth Inventory-Short Form (PTGISF)
into the Malay language and evaluate its psychometric properties for
assessing Malaysian cancer patients in future studies.
Methods: Two parallels
forward and backward translations of the PTGI-SF into the Malay language
were conducted. The test was administered to 195 cancer patients. Reliability
was evaluated by testing internal consistency (Cronbach’s α) and calculating the
test-retest intra-class correlation coefficient, and validity was examined by
determining face, convergent, and discriminant validities and using
confirmatory factor analysis (CFA).
Results: The Malay version of the PTGI-SF
and its five domains demonstrated good internal consistencies and acceptable
test-retest reliability. All 10 items of this version were highly correlated with
their own domains and thus exhibited convergent validity. Discriminant validity
was achieved, as all domains of the Malay PTGI-SF was not highly correlated
with the domains of the Source of Social Support Scale. CFA resulted in a bestfitting
5-factor model.
Conclusion: The Malay version of the PTGI-SF is a
suitable tool for measuring PTG in Malaysian cancer patients.